IL158281A0 - A jasmonate pharmaceutical composition for treatment of cancer - Google Patents

A jasmonate pharmaceutical composition for treatment of cancer

Info

Publication number
IL158281A0
IL158281A0 IL15828102A IL15828102A IL158281A0 IL 158281 A0 IL158281 A0 IL 158281A0 IL 15828102 A IL15828102 A IL 15828102A IL 15828102 A IL15828102 A IL 15828102A IL 158281 A0 IL158281 A0 IL 158281A0
Authority
IL
Israel
Prior art keywords
jasmonate
cancer
glucosyl
alkoxy
treatment
Prior art date
Application number
IL15828102A
Other languages
English (en)
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of IL158281A0 publication Critical patent/IL158281A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15828102A 2001-04-04 2002-03-26 A jasmonate pharmaceutical composition for treatment of cancer IL158281A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/825,347 US6469061B1 (en) 2001-04-04 2001-04-04 Jasmonate pharmaceutical composition for treatment of cancer
PCT/IL2002/000259 WO2002080890A2 (en) 2001-04-04 2002-03-26 A jasmonate pharmaceutical composition for treatment of cancer

Publications (1)

Publication Number Publication Date
IL158281A0 true IL158281A0 (en) 2004-05-12

Family

ID=25243782

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15828102A IL158281A0 (en) 2001-04-04 2002-03-26 A jasmonate pharmaceutical composition for treatment of cancer

Country Status (10)

Country Link
US (1) US6469061B1 (xx)
EP (1) EP1379229B8 (xx)
JP (1) JP4266639B2 (xx)
AT (1) ATE355056T1 (xx)
AU (1) AU2002251451A1 (xx)
CA (1) CA2443623C (xx)
DE (1) DE60218443T2 (xx)
ES (1) ES2280527T3 (xx)
IL (1) IL158281A0 (xx)
WO (1) WO2002080890A2 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224024A1 (en) * 2002-02-04 2003-12-04 Jean-Luc Leveque Compositions comprising cyclopentane derivatives and their use
US8603502B2 (en) * 2002-02-04 2013-12-10 L'oreal S.A. Compositions comprising jasmonic acid derivatives and use of these derivatives
US20030206893A1 (en) * 2002-05-06 2003-11-06 Sohail Malik Cell proliferating agents
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
AU2003299660A1 (en) * 2002-12-16 2004-07-22 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US20040259906A1 (en) * 2003-04-10 2004-12-23 Soner Altiok Methods for controlling the proliferation of cells
TWI329018B (en) * 2003-05-30 2010-08-21 Suntory Holdings Ltd Anti-stress agent
CA2548173A1 (en) * 2003-12-02 2005-06-16 Eliezer Flescher Jasmonate derivative compounds, pharmaceuticals compositions and methods of use thereof
US8147825B2 (en) 2004-01-22 2012-04-03 University Of Miami Topical co-enzyme Q10 formulations and methods of use
US7485666B2 (en) 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7258878B2 (en) * 2004-12-20 2007-08-21 Kimberly-Clark Worldwide, Inc. Anti-microbial composition and methods of use thereof
DK2617714T3 (da) * 2005-12-07 2016-06-27 Univ Ramot Kemiske derivater af jasmonat, farmaceutiske præparater og fremgangsmåder til anvendelse deraf
US8247439B2 (en) * 2005-12-07 2012-08-21 Sepal Pharma Ltd. Jasmonate derivatives, pharmaceutical compositions and methods of use thereof
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
CA2657375A1 (en) * 2006-07-10 2008-01-17 Ramot At Tel-Aviv University Ltd. Combination methods of treating cancer
WO2008111088A2 (en) * 2007-03-15 2008-09-18 Ramot At Tel-Aviv University Ltd. Jasmonate based assays for identifying compounds that selectively inhibit mitochondrial bound hexokinases
FR2921255B1 (fr) * 2007-09-21 2013-12-27 Oreal Utilisation d'un derive d'acide jasmonique a titre d'agent depigmentant
CN102083424B (zh) 2008-04-11 2013-08-28 细胞研究有限公司 诱导癌细胞凋亡的方法和应用
BRPI0804172A2 (pt) * 2008-07-15 2010-07-06 Pereira Lopes Jose Emilio Fehr compostos quìmicos formados a partir de nanoencapsulamentos e complexação de elementos
US9040096B2 (en) 2008-08-28 2015-05-26 The Hershey Company Jasmonic acid compounds in cocoa products
SG10201402288RA (en) 2009-05-11 2014-07-30 Berg Llc Methods for the diagnosis of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
AU2010258223B2 (en) * 2009-06-09 2014-12-04 Ramot At Tel-Aviv University Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
FR2947449B1 (fr) * 2009-07-02 2011-10-21 Oreal Utilisations cosmetiques d'un derive d'acide jasmonique pour la protection anti-oxydante naturelle de la peau, pour le traitement des cheveux et du cuir chevelu
US8679513B2 (en) 2009-07-07 2014-03-25 L'oreal Cosmetic use of a jasmonic acid derivative for treating the hair and the scalp
US20110287116A1 (en) * 2010-05-19 2011-11-24 Broady Health Sciences Llc Use of jasmonates for treating heart failure and related cardiac disorders
TWI489981B (zh) 2010-12-10 2015-07-01 柏萊迪健康科學有限責任公司 使用茉莉酸治療膀胱功能障礙
EP2679230A4 (en) 2011-02-25 2014-07-23 Nanocare Technologies Inc PHARMACEUTICAL FORMULATION WITH JASMONATE FAMILY COMPOUNDS
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
US20120288485A1 (en) * 2011-05-10 2012-11-15 Broady Health Sciences, LLC. Use of jasmone for modulating melatonin production and calcification of the pineal gland
KR20190108189A (ko) 2011-09-16 2019-09-23 나노케어 테크놀로지스 인코퍼레이티드 자스모네이트 화합물의 조성물 및 이의 용도
US8722109B1 (en) 2013-03-12 2014-05-13 Abdul-Wahab Fahad Al-Shemmeri Composition comprising plant extracts and essential oils
CN113797343A (zh) 2013-04-08 2021-12-17 博格有限责任公司 使用辅酶q10联合疗法治疗癌症
HUE050060T2 (hu) 2013-09-04 2020-11-30 Berg Llc Eljárások rák kezelésére koenzim Q10 folyamatos infúziójával
WO2016109779A1 (en) * 2014-12-31 2016-07-07 Nanocare Technologies, Inc. Jasmonate derivatives and compositions thereof
CN108778263A (zh) 2016-03-28 2018-11-09 维达克制药有限公司 用于局部用药的稳定药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118711A (en) 1990-09-27 1992-06-02 International Flavors & Fragrances Inc. Ketone, ketoesters and alcohol in repelling insects; use of aliphatic ester in attracting insects and process and apparatus for determination of insect repellency and attractancy
US5436226A (en) 1993-11-03 1995-07-25 The United States Of America, As Represented By The Secretary Of Agriculture Natural suppression of sprouting in stored potatoes using jasmonates
ATE218276T1 (de) 1996-02-28 2002-06-15 Nippon Zeon Co Wachstumregulator für nutzpflanzen und verfahren zur wachstumsregulation von nutzpflanzen
JP3568325B2 (ja) * 1996-07-12 2004-09-22 株式会社ノエビア 抗アンドロゲン剤及び養毛剤並びに毛髪用化粧料

Also Published As

Publication number Publication date
EP1379229B8 (en) 2007-05-30
CA2443623C (en) 2010-09-14
JP2004525163A (ja) 2004-08-19
DE60218443T2 (de) 2007-10-31
ES2280527T3 (es) 2007-09-16
US6469061B1 (en) 2002-10-22
US20020173470A1 (en) 2002-11-21
EP1379229A2 (en) 2004-01-14
WO2002080890A2 (en) 2002-10-17
JP4266639B2 (ja) 2009-05-20
CA2443623A1 (en) 2002-10-17
ATE355056T1 (de) 2006-03-15
EP1379229B1 (en) 2007-02-28
DE60218443D1 (de) 2007-04-12
AU2002251451A1 (en) 2002-10-21
WO2002080890A3 (en) 2002-12-12

Similar Documents

Publication Publication Date Title
EP1379229B8 (en) A jasmonate pharmaceutical composition for treatment of cancer
AP1422A (en) 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent.
NZ514711A (en) Compounds useful as anti-inflammatory agents
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
TR200000837A2 (tr) Anti-kanser bileşimleri hazırlamak için işlem ve ara maddeler.
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
IL133623A0 (en) Antithrombotic agents
EP0999834A4 (en) ANTITHROMOSIS
EG26287A (en) Fixed solid composition containing pregabalin, glycol or glycerol as moisturizer
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CY1107519T1 (el) Yποκατεστημενες χαλκονες ως θepαπευτικες ενωσεις
GB0202002D0 (en) Use
YU84102A (sh) Nova dibenzoazulen jedinjenja kao inhibitori faktora nekroze tumora
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
DE60114640D1 (en) Antithrombosemittel
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
GR3031114T3 (en) Use of a pregnane derivatives for the treatment of tumours.
WO2001003688A3 (en) Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
ATE492274T1 (de) Cyclohexenon derivate zur behandlung der diabetischen neuropathie
NO20032407L (no) Anvendelse av 6-dimetylaminometyl-1-fenyl- cykloheksanforbindelser for behandling av urininkontinens
MY122570A (en) Benzamide derivatives and drugs containing the same
RS20050954A (xx) Upotreba derivata biciklo/2.2.1/heptana za pripremanje neurozaštitnih farmaceutskih preparata
EE200200688A (et) Akrüloüüldistamütsiini derivaati, mikrotuubulivastast toimeainet ja/või antimetaboliiti sisaldav farmatseutiline kompositsioon, derivaadi kasutamine tuumorivastase ravimi valmistamiseks ning kombineeritud ravimpreparaat

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed